{
    "name": "clofarabine",
    "comment": "Rx",
    "other_names": [
        "Clolar"
    ],
    "classes": [
        "Antineoplastics",
        "Antimetabolite"
    ],
    "source": "https://reference.medscape.com/drug/clolar-clofarabine-342196",
    "pregnancy": {
        "common": [
            "In animal reproduction studies, intravenous administration to pregnant rats and rabbits during organogenesis at doses approximately 0.2 to 1-times maximum recommended human dose of 52 mg/m",
            "Advise pregnant women of potential risk to a fetus; there are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; drug should be used during pregnancy only if potential benefits to mother outweigh potential risks, including those to fetus",
            "Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females: Fherapy can cause embryo-fetal harm when administered to pregnant women; advise female patients to use effective contraception during treatment and for 6 months after last dose",
                    "Males: Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment and for at least 3 months after last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Females: Based on findings from animal studies, drug may impair female fertility; the reversibility of effect on fertility is unknown",
                    "Males: Based on findings from animal studies, drug may impair male fertility; reversibility of effect on fertility is unknown"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of clofarabine in human milk, effects on breastfed child, or on milk production; because of potential for serious adverse reactions in breastfed child including genotoxicity, advise patients not to breastfeed during treatment, and for at least 2 weeks after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Expect typical chemotherapeutic adverse events (diarrhea, nausea/vomiting, bone marrow suppression, risk of tumor lysis syndrome)",
                "Discontinue immediately if clinically significant systemic inflammatory response synd or capillary leak synd develops (may be prevented with prophylactic steroids)",
                "Myelosuppression may be severe and prolonged; monitor complete blood and platelet counts",
                "Serious and fatal cerebral, gastrointestinal and pulmonary hemorrhage; monitor platelets and coagulation parameters and treat accordingly",
                "Monitor for signs and symptoms of infection; severe and fatal sepsis as a result of bone marrow suppression; discontinue therapy promptly if infection occur",
                "Monitor for and discontinue promptly if systemic inflammatory response or capillary leak syndrome suspected",
                "Anticipate and monitor for signs and symptoms of tumor lysis syndrome occur; treat promptly",
                "Monitor for and discontinue if venous occlusive disease of the liver suspected",
                "Monitor liver enzymes and discontinue therapy at first signs of severe hepatotoxicity; discontinue therapy, immediately, for Grade 3 or greater liver enzyme and/or bilirubin elevations; fatal hepatotoxicity may occur",
                "Monitor renal function and interrupt or discontinue if creatinine levels increase or acute renal failure occur",
                "Monitor for signs and symptoms of enterocolitis and treat promptly",
                "Discontinue therapy if exfoliative or bullous rash suspected or if Stevens-Johnson syndrome or toxic epidermal necrolysis suspected",
                "Patients with infection, sepsis, or tumor lysis syndrome may be at increased risk of renal toxicity when treated receiving therapy; monitor patients for renal toxicity and interrupt or discontinue therapy as necessary",
                "Avoid pregnancy",
                "Hepatitis and hepatic failure reported",
                "Renal impairment"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "clofarabine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bacitracin",
            "description": {
                "common": "clofarabine and bacitracin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug. Avoid concurrent use of bacitracin with other nephrotoxic drugs"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "clofarabine, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "clofarabine, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "clofarabine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "clofarabine, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of clofarabine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, clofarabine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "clofarabine, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "clofarabine, tofacitinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "clofarabine decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "clofarabine decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "clofarabine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza A (H5N1) vaccine",
            "description": {
                "common": "clofarabine decreases effects of influenza A (H5N1) vaccine by Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine (H5N1), adjuvanted",
            "description": {
                "common": "clofarabine decreases effects of influenza virus vaccine (H5N1), adjuvanted by Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, clofarabine.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peramivir",
            "description": {
                "common": "clofarabine increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and clofarabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, clofarabine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, clofarabine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zidovudine",
            "description": {
                "common": "clofarabine, zidovudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of myelosuppression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "benazepril",
            "description": {
                "common": "clofarabine, benazepril.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May increase risk of hypotension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "captopril",
            "description": {
                "common": "clofarabine, captopril.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May increase risk of hypotension."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Infection",
            "percent": "83"
        },
        {
            "name": "bacterial",
            "percent": "83"
        },
        {
            "name": "viral",
            "percent": "75"
        },
        {
            "name": "fungal",
            "percent": "83"
        },
        {
            "name": "Vomiting",
            "percent": "88"
        },
        {
            "name": "Nausea",
            "percent": "82"
        },
        {
            "name": "Anemia",
            "percent": "57"
        },
        {
            "name": "Leukopenia",
            "percent": "81"
        },
        {
            "name": "Lymphopenia",
            "percent": "53"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "8-35"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "30"
        },
        {
            "name": "Diarrhea",
            "percent": "43"
        },
        {
            "name": "Abdominal pain",
            "percent": "34"
        },
        {
            "name": "Anorexia",
            "percent": "43"
        },
        {
            "name": "Dermatitis",
            "percent": "39"
        },
        {
            "name": "Pruritus",
            "percent": "12"
        },
        {
            "name": "Fatigue",
            "percent": "19"
        },
        {
            "name": "Headache",
            "percent": "13"
        },
        {
            "name": "Pyrexia",
            "percent": "29"
        },
        {
            "name": "Edema",
            "percent": "21"
        },
        {
            "name": "Flushing",
            "percent": "15"
        },
        {
            "name": "HTN",
            "percent": "11"
        },
        {
            "name": "Hypotension",
            "percent": "26"
        },
        {
            "name": "Anxiety",
            "percent": "16"
        },
        {
            "name": "Pain",
            "percent": "14"
        },
        {
            "name": "Erythema",
            "percent": "16"
        },
        {
            "name": "Petechiae",
            "percent": "11"
        },
        {
            "name": "Palmar",
            "percent": "13"
        },
        {
            "name": "plantar erythrodysesthesia syndrome",
            "percent": "12"
        },
        {
            "name": "Gingival bleeding",
            "percent": "13"
        },
        {
            "name": "Mucositis",
            "percent": "30"
        },
        {
            "name": "Oral candidiasis",
            "percent": "14"
        },
        {
            "name": "Cough",
            "percent": "10"
        },
        {
            "name": "Dyspnea",
            "percent": "10"
        },
        {
            "name": "Pleural effusion",
            "percent": "10"
        },
        {
            "name": "Hepatobiliary disorder",
            "percent": "10"
        },
        {
            "name": "Hematuria",
            "percent": "10"
        },
        {
            "name": "Limb pain",
            "percent": "10"
        },
        {
            "name": "Myalgia",
            "percent": "10"
        },
        {
            "name": "Contusion",
            "percent": "8"
        },
        {
            "name": "Injection site pain",
            "percent": "5"
        },
        {
            "name": "Transfusion reaction",
            "percent": null
        },
        {
            "name": "Back pain",
            "percent": null
        },
        {
            "name": "Bacteremia",
            "percent": null
        },
        {
            "name": "Herpes simplex infections",
            "percent": null
        },
        {
            "name": "Sepsis",
            "percent": null
        },
        {
            "name": "Irritability",
            "percent": null
        },
        {
            "name": "Lethargy",
            "percent": null
        },
        {
            "name": "Somnolence",
            "percent": null
        },
        {
            "name": "Cellulitis",
            "percent": null
        },
        {
            "name": "Agitation",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Gastrointestinal hemorrhage including fatalities",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Occurrences of Stevens",
            "percent": null
        },
        {
            "name": "Johnson Syndrome and toxic epidermal necrolysis",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Hyponatremia",
            "percent": null
        },
        {
            "name": "Hepatitis and hepatic failure",
            "percent": null
        },
        {
            "name": "Cardiovascular disorders",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Chills",
            "percent": null
        }
    ]
}